Search

Your search keyword '"Denton, K. M."' showing total 5 results
Start Over Author "Denton, K. M." Publication Year Range Last 10 years
5 results on '"Denton, K. M."'

2. Renal Denervation Update From the International Sympathetic Nervous System Summit:JACC State-of-the-Art Review

Author

Kiuchi M. G., Esler M. D., Fink G. D., Osborn J. W., Banek C. T., Bohm M., Denton K. M., DiBona G. F., Everett T. H., Grassi G., Katholi R. E., Knuepfer M. M., Kopp U. C., Lefer D. J., Lohmeier T. E., May C. N., Mahfoud F., Paton J. F. R., Schmieder R. E., Pellegrino P. R., Sharabi Y., Schlaich M. P., Kiuchi, M, Esler, M, Fink, G, Osborn, J, Banek, C, Bohm, M, Denton, K, Dibona, G, Everett, T, Grassi, G, Katholi, R, Knuepfer, M, Kopp, U, Lefer, D, Lohmeier, T, May, C, Mahfoud, F, Paton, J, Schmieder, R, Pellegrino, P, Sharabi, Y, and Schlaich, M

Subjects
sympathetic nervous system, hypertension, cardiovascular disease, blood pressure, renal denervation
Abstract

Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

Published
2019

3. Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review

Author

Kiuchi, M, Esler, M, Fink, G, Osborn, J, Banek, C, Bohm, M, Denton, K, Dibona, G, Everett, T, Grassi, G, Katholi, R, Knuepfer, M, Kopp, U, Lefer, D, Lohmeier, T, May, C, Mahfoud, F, Paton, J, Schmieder, R, Pellegrino, P, Sharabi, Y, Schlaich, M, Kiuchi M. G., Esler M. D., Fink G. D., Osborn J. W., Banek C. T., Bohm M., Denton K. M., DiBona G. F., Everett T. H., Grassi G., Katholi R. E., Knuepfer M. M., Kopp U. C., Lefer D. J., Lohmeier T. E., May C. N., Mahfoud F., Paton J. F. R., Schmieder R. E., Pellegrino P. R., Sharabi Y., Schlaich M. P., Kiuchi, M, Esler, M, Fink, G, Osborn, J, Banek, C, Bohm, M, Denton, K, Dibona, G, Everett, T, Grassi, G, Katholi, R, Knuepfer, M, Kopp, U, Lefer, D, Lohmeier, T, May, C, Mahfoud, F, Paton, J, Schmieder, R, Pellegrino, P, Sharabi, Y, Schlaich, M, Kiuchi M. G., Esler M. D., Fink G. D., Osborn J. W., Banek C. T., Bohm M., Denton K. M., DiBona G. F., Everett T. H., Grassi G., Katholi R. E., Knuepfer M. M., Kopp U. C., Lefer D. J., Lohmeier T. E., May C. N., Mahfoud F., Paton J. F. R., Schmieder R. E., Pellegrino P. R., Sharabi Y., and Schlaich M. P.

Abstract

Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

Published
2019

5. Anti-fibrotic actions of relaxin.

Author

Samuel, C S, Royce, S G, Hewitson, T D, Denton, K M, Cooney, T E, and Bennett, R G

Subjects
RELAXIN, FIBROSIS, WOUND healing, CYTOKINES, METALLOPROTEINASES, THERAPEUTICS
Abstract

Fibrosis refers to the hardening or scarring of tissues that usually results from aberrant wound healing in response to organ injury, and its manifestations in various organs have collectively been estimated to contribute to around 45-50% of deaths in the Western world. Despite this, there is currently no effective cure for the tissue structural and functional damage induced by fibrosis-related disorders. Relaxin meets several criteria of an effective anti-fibrotic based on its specific ability to inhibit pro-fibrotic cytokine and/or growth factor-mediated, but not normal/unstimulated, fibroblast proliferation, differentiation and matrix production. Furthermore, relaxin augments matrix degradation through its ability to up-regulate the release and activation of various matrix-degrading matrix metalloproteinases and/or being able to down-regulate tissue inhibitor of metalloproteinase activity. Relaxin can also indirectly suppress fibrosis through its other well-known (anti-inflammatory, antioxidant, anti-hypertrophic, anti-apoptotic, angiogenic, wound healing and vasodilator) properties. This review will outline the organ-specific and general anti-fibrotic significance of exogenously administered relaxin and its mechanisms of action that have been documented in various non-reproductive organs such as the cardiovascular system, kidney, lung, liver, skin and tendons. In addition, it will outline the influence of sex on relaxin's anti-fibrotic actions, highlighting its potential as an emerging anti-fibrotic therapeutic. Linked Articles This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results